Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
The downs are more pronounced than the ups as the macroeconomic climate turns against big pharma and biotech.